Stay updated with breaking news from Genome Project Write. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
To help celebrate GEN’s 40th Anniversary with this special October issue, we asked scientists and business professionals in academia and industry to give us their reflections, impressions, and insights on the biotechnology industry and the life sciences.
E-Mail NEW YORK, May 12, 2021 -- A new Computer Aided Design (CAD) platform for whole genome design is being launched by two pioneers in the world of biotech: Genome Project-write (GP-write) and Twist Bioscience (NASDAQ: TWST). The technology is expected to open up new frontiers in genome research with real world applications to advance development of therapeutics and solutions for environmental health. The CAD technology will be an important development along the path to more facile writing of genomes, by eliminating a host of barriers that hinder genome design. Current platforms can be ...
CAD Platform Developed by GP-Write and Twist to Launch Large Genome Projects May 12, 2021 Share A new Computer Aided Design (CAD) platform for whole genome design is being launched by Genome Project-write (GP-write) and Twist Bioscience. The technology is expected to open up new frontiers in genome research with real-world applications to advance the development of therapeutics and solutions for environmental health. The CAD technology will be an important development along the path to more facile writing of genomes, by eliminating a host of barriers that hinder genome design. Current platfor...
Private equity: The booming biotech sector Investment in biotech is booming. In Europe, the biotechnology and healthcare sector accounted for 20% of overall private equity investment in the first half of 2020, according to data from funds trade body Invest Europe. Investors in the field are faced not only with financial and ethical dilemmas, but the risks posed by the presence of bad actors. Andrew Hessel, a microbiologist, tells the latest issue of Funds Europe that, as with all developing technologies, the risks entailed are ever-evolving. “The core of the technology is agnostic, it...
Private markets: Biotech funds point to the future Healthcare has had a year like no other for at least two reasons. The first is obvious. The second is all about investment. In April, for example, healthcare ETFs saw their highest level of inflows – $7.3 billion at the global level. And although this amounted to just $0.5 billion in Europe, even that was a regional record. BlackRock, which published the numbers, said the interest in medical device production and in pharmaceutical innovation had offered investors two rationales for investing in the sector. At Goldman Sachs Asset Managemen...